As we read more and more about variants and the prognosis for this pandemic and the part RVX 208 could play in it, I just wanted to re-post something I came across a couple of weeks ago.  Long COVID and how patients who have "recovered" fall victim to the disease months and months later, and it seems to center around Diabetes, CKD and MACE.  If this pandemic meets some of our worst fears, then I can't help but think that RVX 208 can make a meaningful impact as a long-term therapeutic for COVID patients

COVID 19 ?

One of the very disturbing aspects of this disease has to do with the number of older folks who caught the virus, were hospitalized, released from hospital, and then subsequently re-admitted months later....and then died from the lingering, devastating consequences.  Again, in my non-scientific opinion, this is where RVX 208 could really be of some benefit.

Here is a recent study of 47,780 patients hospitalized for COVID 19, then released.  After 140 day follow up 29.4% were re-admitted and 12.3% died.  Looking at the details it appears to me that RVX 208 would be effective in addressing the factors that threaten their lives (i.e. Diabetes, MACE, CKD)

https://twitter.com/kamleshkhunti/status/1350779893659930624

https://www.medrxiv.org/content/10.1101/2021.01.15.21249885v1.full-text

...and finally..

this , from Eric Topol on the J&J vaccine (hint - its more effective than the headline numbers suggest)

"Then we reviewed the outstanding finding in their data set. There were approximately 40-60 hospitalizations and deaths in the whole trial. All in the placebo group. Period. Even those occurring in South Africa. That is *great news* /3"

read the whole thread here:

https://twitter.com/EricTopol/status/1355627162678644739